Follow NovoCure to never miss an important update.
A medical journal published new data from the company's Phase 3 trial for pancreatic cancer, a study used to test if a treatment is safe and effective. The analysis focused on how patients felt during treatment, finding that adding the wearable device to standard chemotherapy did not make pain worse or reduce their overall quality of life compared to chemotherapy alone.
This is a win for the company because its treatment requires patients to wear a device for most of the day. Proving that this does not add a physical or emotional burden is essential for getting doctors to prescribe it and for winning over insurance companies. While the main goal of any cancer drug is to help patients live longer, showing that the extra time is spent in relative comfort is a major part of making the therapy a standard choice for aggressive tumors.
Source: Business Wire
The FDA has rejected Novocure’s application to use its wearable electric-field device to treat patients whose lung cancer has spread to the brain. In a formal letter, the agency said it is not yet convinced the treatment provides a clear enough clinical benefit to justify approval.
This is a significant setback because moving beyond its original niche in brain cancer is the core of Novocure's growth plan. While the company has seen success in other areas, this rejection creates a delay in a major market and forces management to either provide more data or find a new path forward for this specific use. For long-term owners, the focus now shifts to whether the company can address the FDA's concerns without needing a new, expensive clinical trial.
Source: Business Wire
After NovoCure reported its October results, we updated our fair value and raised our quality score to 4. 0. We increased our rating for how the company uses its capital and for its management team. We added the contribution of the Japanese market to what we track after it provided nearly half of the revenue for its newest therapy.
Novocure reported a loss of 9 cents per share, which was much better than the 23 cent loss analysts expected. Revenue grew 16 percent to $193 million, fueled by a record number of patients using its wearable cancer-treating devices. The company now expects full-year revenue to reach as high as $743 million, up from its previous targets.
This growth is a vital sign for the business as it moves beyond its original focus on brain cancer. The company also secured approval in Japan for its pancreatic cancer treatment, which helps open a major new market. While the stock fell about 5 percent today alongside a broader market drop, the underlying business is showing it can grow its patient base while moving closer to its goal of becoming profitable by late 2028.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Novocure has entered a deal with Verastem Oncology to run a clinical trial for patients with locally advanced pancreatic cancer. The study will combine Novocure's wearable device, which uses electric fields to disrupt cancer cell division, with an experimental oral drug and standard chemotherapy.
This is a logical step for the company following its recent FDA approval for pancreatic cancer. By testing its technology alongside new types of drugs like KRAS inhibitors, which target specific genetic mutations in tumors, Novocure is trying to prove its device should be a standard part of complex treatment plans. If the combination shows better results than drugs alone, it could help the company reach more patients in this difficult-to-treat market.
Source: Business Wire
Management has a clear habit of setting conservative targets and then beating them, having topped analyst profit estimates in six of the last eight quarters.
| Expectation | |
|---|---|
| EPS | $-0.23 |
| Revenue | $190M |